Commercialization: Page 2
-
AstraZeneca’s newest asthma launch fills a gap as generics chip away at respiratory flagships
A longtime leader in the respiratory space, AstraZeneca has hammered another stake in the ground with its newest asthma treatment, Airsupra.
By Michael Gibney • Jan. 24, 2023 -
Drug price negotiations: 5 key dates to watch
As the CMS readies its new program for lowering drug costs, these are the moments that will matter most to pharma companies.
By Kelly Bilodeau • Jan. 23, 2023 -
Q&A
Already on a roll in oncology, Astellas hunts for big wins in other areas
With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point.
By Karissa Waddick • Jan. 23, 2023 -
Sponsored by LiveWorld
Tactics for growing your walled garden presence
Cultivate relationships with HCPs in gated social platforms with content that will thrive.
Jan. 23, 2023 -
FDA’s 2022 drug approvals fall short of recent norms
The U.S. agency’s lower number of novel drug approvals followed several controversies surrounding a 2021 Alzheimer’s approval.
By Alexandra Pecci • Jan. 19, 2023 -
After ‘limping along,’ Novavax sees a path forward
With a new CEO and a long-term booster strategy, the company believes there’s plenty of room to grow in the COVID-19 vaccine space.
By Meagan Parrish • Jan. 18, 2023 -
Can pharma quit Twitter? Social strategy evolves as Musk changes the platform
A breakdown of how Twitter’s recent shifts are impacting pharma, and how the industry should navigate the platform in 2023.
By Karissa Waddick • Dec. 16, 2022 -
Podcast
Woman of the Week: Exelixis’ Dr. Vicki Goodman
With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.
By Taren Grom • Dec. 14, 2022 -
Q&A // First 90 Days
Dr. Sy Pretorius, Eversana’s new COO, is flipping the script on his career
With a long history in the clinical space, Pretorius is now applying those deep insights to the commercial side of the business.
By Taren Grom • Dec. 9, 2022 -
An FDA proposal could make OTC switches easier. Here’s what the industry has to say
How the FDA’s proposal to create a new OTC approval pathway could impact the pharma industry.
By Karissa Waddick • Dec. 5, 2022 -
Executive changes at Teva, Eversana could spell commercial growth in the new year
With their latest personnel moves, these life sciences companies are preparing for major business shifts.
By Karissa Waddick • Nov. 23, 2022 -
4 pioneering social media campaigns in pharma this year
The key to a great social media campaign is often simplicity, and these pharma companies hit the nail on the head with unique strategies that aim to educate.
By Karissa Waddick • Nov. 17, 2022 -
Retrieved from Google image.
While DCTs get all the hype, some industry insiders say the future is a digital hybrid
Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.
By Michael Gibney • Nov. 1, 2022 -
Podcast
Woman of the Week: Ironwood Pharmaceuticals’ Diane Stroehmann
The VP of regulatory affairs and global patient safety explains why her line of work lets her do “a little of everything,” and the company’s plans to score a new approval for its blockbuster drug.
By Taren Grom • Oct. 26, 2022 -
Backed by celebrity interest, Novo is finding new success in weight loss — while staying true to its roots
The company's head of U.S. and Canadian operations explains how it’s evolving its game plan after 100 years in the insulin space.
By Meagan Parrish • Oct. 25, 2022 -
Biosimilars will gain ground in 2023 with Humira launches — and that’s just the beginning
In Amgen's 2022 Biosimilars Trend Report, the company tracks the progress and potential of the copycat drugs as they reach a pivotal moment.
By Michael Gibney • Oct. 24, 2022 -
Think your company could be on HHS’ drug price negotiation list? Here’s how to navigate next steps
Know what to expect from the CMS over the next few months as it implements the drug reforms laid out in the Inflation Reduction Act.
By Karissa Waddick • Oct. 18, 2022 -
Q&A // Biotech Spotlight
Citius Pharmaceuticals sees golden opportunities in late-stage specialty assets
CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.
By Karissa Waddick • Oct. 11, 2022 -
Q&A
Her antibiotic company failed. Now she’s helping others avoid the same fate.
The chief of R&D at CARB-X explains why she believes small antibiotics companies can succeed despite market turmoil.
By Karissa Waddick • Oct. 6, 2022 -
Making Moves
C-suite shake-ups at 23andMe, Moderna signal new stages of growth
With their latest personnel moves, these life sciences companies are preparing for major business shifts.
By Karissa Waddick • Oct. 5, 2022 -
Q&A
Compass has the most advanced psychedelic drug in trials — but it needs a new approach to rollout to make it a success
The company's CEO, Kabir Nath, discusses potential roadblocks to commecialization that await its psilocybin treatment for depression.
By Meagan Parrish • Sept. 27, 2022 -
Sponsored by EVERSANA
3 keys to value for unlocking the promise of cell therapies
There is no question about the incredible clinical impact cell therapies can have on the lives of patients. However, this impact is the result of innovation that does not equate to a simple, straightforward commercialization process.
Sept. 26, 2022 -
Podcast
Woman of the Week: Foresite Capital’s Cindy Mesaros
The longtime marketing pro details her fascinating career journey and how she’s positioning early stage health companies to thrive.
By Taren Grom • Sept. 7, 2022 -
Moderna’s lawsuit against Pfizer and BioNTech explained in 10 quotes
The biotech says that its competitors’ COVID-19 vaccine copied proprietary mRNA technology. Here’s a breakdown of the case.
By Karissa Waddick • Aug. 31, 2022 -
Hurdles remain in biosims market — but Alvotech is undeterred
The biosimilar developer is advancing a pipeline with high growth potential, including a copycat of Humira.
By Kelly Bilodeau • Aug. 29, 2022